Stryker Co. (NYSE:SYK) Shares Bought by Seelaus Asset Management LLC

Seelaus Asset Management LLC raised its holdings in shares of Stryker Co. (NYSE:SYK) by 2.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,779 shares of the medical technology company’s stock after purchasing an additional 60 shares during the period. Stryker accounts for approximately 0.9% of Seelaus Asset Management LLC’s investment portfolio, making the stock its 20th biggest holding. Seelaus Asset Management LLC’s holdings in Stryker were worth $1,004,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Lord Abbett & CO. LLC raised its stake in Stryker by 5.0% in the first quarter. Lord Abbett & CO. LLC now owns 821 shares of the medical technology company’s stock valued at $294,000 after buying an additional 39 shares during the last quarter. Nwam LLC raised its position in shares of Stryker by 2.1% in the 1st quarter. Nwam LLC now owns 2,214 shares of the medical technology company’s stock valued at $740,000 after purchasing an additional 46 shares during the last quarter. Tocqueville Asset Management L.P. boosted its stake in Stryker by 6.2% in the 1st quarter. Tocqueville Asset Management L.P. now owns 2,222 shares of the medical technology company’s stock worth $795,000 after purchasing an additional 130 shares in the last quarter. M&G Plc purchased a new stake in Stryker during the 1st quarter worth approximately $11,534,000. Finally, First Foundation Advisors increased its stake in Stryker by 49.6% during the 1st quarter. First Foundation Advisors now owns 1,343 shares of the medical technology company’s stock valued at $481,000 after purchasing an additional 445 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, VP M Kathryn Fink sold 7,347 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the sale, the vice president now directly owns 10,042 shares in the company, valued at approximately $3,685,213.16. The trade was a 42.25 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now directly owns 9,069 shares of the company’s stock, valued at $3,219,495. The trade was a 6.21 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 67,381 shares of company stock worth $24,825,275. Company insiders own 5.90% of the company’s stock.

Stryker Price Performance

Shares of Stryker stock opened at $390.08 on Friday. The firm has a market cap of $148.71 billion, a PE ratio of 41.81, a P/E/G ratio of 2.89 and a beta of 0.91. Stryker Co. has a twelve month low of $282.35 and a twelve month high of $392.70. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The business has a 50-day moving average price of $364.07 and a 200 day moving average price of $347.33.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The business had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. During the same period in the previous year, the business earned $2.46 earnings per share. The business’s revenue was up 11.9% compared to the same quarter last year. Sell-side analysts predict that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently commented on SYK. Truist Financial lifted their price objective on shares of Stryker from $370.00 to $380.00 and gave the stock a “hold” rating in a research note on Wednesday, October 30th. Barclays lifted their price target on Stryker from $402.00 to $418.00 and gave the stock an “overweight” rating in a research report on Thursday, October 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Thursday. Stifel Nicolaus decreased their target price on Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Finally, BTIG Research increased their price target on shares of Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.